| Project/Area Number |
23592090
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Kawasaki Medical School (2012-2013)
Okayama University (2011) |
|---|
Principal Investigator |
ONO Shigeki 川崎医科大学, 医学部, 教授 (40335625)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUROZMI Kazuhiko 岡山大学, 医歯(薬)学総合研究科, 講師 (20509608)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
DATE Isao 岡山大学, 医歯(薬)学総合研究科, 教授 (70236785)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 脳血管障害学 / 分子標的薬 |
|---|
| Research Abstract |
The MCS ulturing and the usage of MSC for human, rats, and mice were comfirmed. Cikengitide was supplied freely by NCI and Merc. In this study, we were able to create the MCAO animal model. In behavioral assessment, we obtained the standard value of Limb placement test and rotarod test in the MSC single treatment group using by this MCAO model. The expression of BDNF, GDNF, NT3 and CNTF was also confirmed in MSC cells by using ELISA.
|
